Publication Name	World Journal of Gastroenterology
Manuscript ID	101933
Country	Russia

Received	2024-10-01 13:07
Peer-Review Started	2024-10-01 13:07
To Make the First Decision
Return for Revision	2024-11-02 02:07
Revised	2024-11-08 13:47
Second Decision	2024-12-06 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-06 06:23
Articles in Press	2024-12-06 06:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-12 00:37
Publish the Manuscript Online	2024-12-30 06:47

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs
Manuscript Source	Invited Manuscript
All Author List	Sergey M Kotelevets
ORCID	Author(s) ORCID Number Sergey M Kotelevets http://orcid.org/0000-0003-4915-6869
Funding Agency and Grant Number
Corresponding Author	Sergey M Kotelevets, MD, Department of Therapy, North Caucasus State Academy, 75/32 Lenina Street, Cherkessk 369000, Russia. smkotelevets@mail.ru
Key Words	Epidemiology; Gastroesophageal reflux disease; Proton pump inhibitor; Potassium-competitive acid blocker; Risk-benefit; Gastroprotection; Compensatory mechanisms; Helicobacter pylori infection; Sanogenesis
Core Tip	Helicobacter pylori infection has a protective effect on gastroesophageal reflux disease. Both of these diseases have a very high incidence and prevalence. The main obstacle to effective treatment Helicobacter pylori infection and gastroesophageal reflux disease is the possible side effects after use of proton pump inhibitors (PPIs). The article provides a precise analysis of scientific reviews and meta-analyses, as well as experimental scientific morphological studies on this topic. The author presented his original field of vision. He convincingly substantiated his opinion, proposed to interpret possible morphological and functional changes in the gastric mucosa after long-term use of PPIs as compensatory mechanisms of sanogenesis. This field of view will increase the number of indications for the use of PPIs and other antisecretory drugs.
Publish Date	2024-12-30 06:47
Citation	<p>Kotelevets SM. Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs. <i>World J Gastroenterol</i> 2025; 31(4): 101933</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i4/101933.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i4.101933

Full Article (PDF)	WJG-31-101933-with-cover.pdf
Manuscript File	101933_Auto_Edited_013933.docx
Answering Reviewers	101933-answering-reviewers.pdf
Audio Core Tip	101933-audio.wma
Conflict-of-Interest Disclosure Form	101933-conflict-of-interest-statement.pdf
Copyright License Agreement	101933-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	101933-non-native-speakers.pdf
Peer-review Report	101933-peer-reviews.pdf
Scientific Misconduct Check	101933-scientific-misconduct-check.png
Scientific Editor Work List	101933-scientific-editor-work-list.pdf
CrossCheck Report	101933-crosscheck-report.pdf